Financhill
Sell
46

ASND Quote, Financials, Valuation and Earnings

Last price:
$152.81
Seasonality move :
-9.72%
Day range:
$151.22 - $155.39
52-week range:
$111.09 - $158.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.60x
P/B ratio:
--
Volume:
405.8K
Avg. volume:
522.2K
1-year change:
2.06%
Market cap:
$9.2B
Revenue:
$393.6M
EPS (TTM):
-$7.13

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ASND
Ascendis Pharma AS
$135.6M -$1.41 -2.6% -34.91% $211.23
AKTX
Akari Therapeutics PLC
-- -- -- -- --
BCYC
Bicycle Therapeutics PLC
$7.9M -$0.82 -55.59% -31.65% $29.55
EVAX
Evaxion Biotech AS
$1.7M -$0.15 6174.51% -98% $13.25
NVO
Novo Nordisk AS
$12.1B $0.97 23.24% 6.35% $112.90
VRNA
Verona Pharma PLC
$68.4M -$0.02 -- -89.84% $81.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ASND
Ascendis Pharma AS
$152.98 $211.23 $9.2B -- $0.00 0% 22.60x
AKTX
Akari Therapeutics PLC
$1.05 -- $26M -- $0.00 0% --
BCYC
Bicycle Therapeutics PLC
$9.65 $29.55 $667.8M -- $0.00 0% 15.91x
EVAX
Evaxion Biotech AS
$1.78 $13.25 $11.2M -- $0.00 0% 0.49x
NVO
Novo Nordisk AS
$77.15 $112.90 $342.5B 23.50x $0.52 1.88% 8.18x
VRNA
Verona Pharma PLC
$61.39 $81.00 $5.2B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ASND
Ascendis Pharma AS
114.08% 0.763 10.82% 0.81x
AKTX
Akari Therapeutics PLC
-- 0.585 -- --
BCYC
Bicycle Therapeutics PLC
-- 0.789 -- 13.61x
EVAX
Evaxion Biotech AS
-- -2.040 -- 2.80x
NVO
Novo Nordisk AS
40.09% 0.871 3.51% 0.52x
VRNA
Verona Pharma PLC
37.04% -0.759 3.06% 10.24x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ASND
Ascendis Pharma AS
$170.4M $408.3K -69.61% -880.05% -24.36% -$90.9M
AKTX
Akari Therapeutics PLC
-- -$1.9M -- -- -- -$1.5M
BCYC
Bicycle Therapeutics PLC
-- -$67.1M -25.48% -26.21% -1426.21% -$9.8M
EVAX
Evaxion Biotech AS
-- -$1.7M -238.97% -- -54.59% --
NVO
Novo Nordisk AS
$10.4B $5.2B 60.28% 86.85% 40.78% -$786.4M
VRNA
Verona Pharma PLC
$34.6M -$17.8M -60.44% -88.7% -41.57% -$29.4M

Ascendis Pharma AS vs. Competitors

  • Which has Higher Returns ASND or AKTX?

    Akari Therapeutics PLC has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -880.05% beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
    AKTX
    Akari Therapeutics PLC
    -- -$0.24 --
  • What do Analysts Say About ASND or AKTX?

    Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 7519.05%. Given that Akari Therapeutics PLC has higher upside potential than Ascendis Pharma AS, analysts believe Akari Therapeutics PLC is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ASND
    Ascendis Pharma AS
    12 1 0
    AKTX
    Akari Therapeutics PLC
    0 0 0
  • Is ASND or AKTX More Risky?

    Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.528%.

  • Which is a Better Dividend Stock ASND or AKTX?

    Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ASND or AKTX?

    Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Ascendis Pharma AS's net income of -$41M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ASND
    Ascendis Pharma AS
    22.60x -- $185.4M -$41M
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$2.9M
  • Which has Higher Returns ASND or BCYC?

    Bicycle Therapeutics PLC has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -1398.44%. Ascendis Pharma AS's return on equity of -880.05% beat Bicycle Therapeutics PLC's return on equity of -26.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
    BCYC
    Bicycle Therapeutics PLC
    -- -$0.75 $793.1M
  • What do Analysts Say About ASND or BCYC?

    Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 206.17%. Given that Bicycle Therapeutics PLC has higher upside potential than Ascendis Pharma AS, analysts believe Bicycle Therapeutics PLC is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ASND
    Ascendis Pharma AS
    12 1 0
    BCYC
    Bicycle Therapeutics PLC
    5 3 0
  • Is ASND or BCYC More Risky?

    Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.

  • Which is a Better Dividend Stock ASND or BCYC?

    Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ASND or BCYC?

    Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Ascendis Pharma AS's net income of -$41M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus 15.91x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ASND
    Ascendis Pharma AS
    22.60x -- $185.4M -$41M
    BCYC
    Bicycle Therapeutics PLC
    15.91x -- $3.7M -$51.9M
  • Which has Higher Returns ASND or EVAX?

    Evaxion Biotech AS has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -64.14%. Ascendis Pharma AS's return on equity of -880.05% beat Evaxion Biotech AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
  • What do Analysts Say About ASND or EVAX?

    Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 644.38%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ASND
    Ascendis Pharma AS
    12 1 0
    EVAX
    Evaxion Biotech AS
    1 0 0
  • Is ASND or EVAX More Risky?

    Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ASND or EVAX?

    Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ASND or EVAX?

    Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Ascendis Pharma AS's net income of -$41M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus 0.49x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ASND
    Ascendis Pharma AS
    22.60x -- $185.4M -$41M
    EVAX
    Evaxion Biotech AS
    0.49x -- $3M -$1.9M
  • Which has Higher Returns ASND or NVO?

    Novo Nordisk AS has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of 32.95%. Ascendis Pharma AS's return on equity of -880.05% beat Novo Nordisk AS's return on equity of 86.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
    NVO
    Novo Nordisk AS
    84.8% $0.91 $33.4B
  • What do Analysts Say About ASND or NVO?

    Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 48.19%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ASND
    Ascendis Pharma AS
    12 1 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is ASND or NVO More Risky?

    Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

  • Which is a Better Dividend Stock ASND or NVO?

    Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.88% to investors and pays a quarterly dividend of $0.52 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ASND or NVO?

    Ascendis Pharma AS quarterly revenues are $185.4M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Ascendis Pharma AS's net income of -$41M is lower than Novo Nordisk AS's net income of $4B. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus 8.18x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ASND
    Ascendis Pharma AS
    22.60x -- $185.4M -$41M
    NVO
    Novo Nordisk AS
    8.18x 23.50x $12.2B $4B
  • Which has Higher Returns ASND or VRNA?

    Verona Pharma PLC has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -92.29%. Ascendis Pharma AS's return on equity of -880.05% beat Verona Pharma PLC's return on equity of -88.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
    VRNA
    Verona Pharma PLC
    94.44% -$0.40 $324.9M
  • What do Analysts Say About ASND or VRNA?

    Ascendis Pharma AS has a consensus price target of $211.23, signalling upside risk potential of 38.08%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 31.94%. Given that Ascendis Pharma AS has higher upside potential than Verona Pharma PLC, analysts believe Ascendis Pharma AS is more attractive than Verona Pharma PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ASND
    Ascendis Pharma AS
    12 1 0
    VRNA
    Verona Pharma PLC
    5 0 0
  • Is ASND or VRNA More Risky?

    Ascendis Pharma AS has a beta of 0.616, which suggesting that the stock is 38.413% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.

  • Which is a Better Dividend Stock ASND or VRNA?

    Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ASND or VRNA?

    Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Verona Pharma PLC quarterly revenues of $36.7M. Ascendis Pharma AS's net income of -$41M is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.60x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ASND
    Ascendis Pharma AS
    22.60x -- $185.4M -$41M
    VRNA
    Verona Pharma PLC
    -- -- $36.7M -$33.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Is Goldman Sachs Stock a Buy Sell or Hold?
Is Goldman Sachs Stock a Buy Sell or Hold?

When the Federal Reserve started hiking rates in 2022, banks’…

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock